A Phase II Study of First-Line Chemotherapy and Panitumumab in Advanced NSCLC Selected by Mutational Status
Advanced NSCLC holds a very poor prognosis with a moderate response rate to standard
chemotherapy. The standard first-line treatment for advanced NSCLC is platinum based
combination chemotherapy. The response rates are less than 30% and a substantial amount of
patients will experience unnecessary toxicity in terms of e.g. nausea, vomiting,
neuropathies or a considerable risk of renal toxicity. The median progression free survival
is 3-4 months and consequently, the median overall survival is less than one year (Hotta et
al 2007). Addition of new biological agents to standard chemotherapy regimens may improve
the outcome for these patients.
Interventional
Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate
Up to 3 years
No
Denmark: Danish Medicines Agency
2009-015068-32
NCT01038037
January 2010
December 2013
Name | Location |
---|